Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex, class II, DR beta 1 chain (HLA-DRB1*10:01) (HLA-DR10)
- Target
- HLA-DR10
- Molecular classification
- Receptor (specifically, cell surface glycoprotein), Major histocompatibility complex class II molecule, Antigen-presenting molecule
01
Overview
HLA-DR10 refers to a specific serotype and protein of the human leukocyte antigen (HLA) system, belonging to the class II major histocompatibility complex (MHC) family. It is comprised of an alpha and beta chain (with DRB1*1001 as the defining beta chain), and is expressed on antigen-presenting cells such as B lymphocytes. HLA-DR10 presents exogenous peptide antigens to CD4+ T helper cells, which is essential for adaptive immune responses. The DR10 serotype is implicated in predisposition to certain autoimmune and malignant diseases, and has been experimentally targeted using antibodies (such as Lym-1) and synthetic peptide-like ligands. HLA-DR10 is notable for its high polymorphism and immunological specificity
- Other names
- HLA-DR10HLA-DRB1*10:01DRB1*1001DR10MHC class II HLA-DR beta 1 chainHLA-DRw10-beta
02
Mechanism of action
Antibody-mediated recognition and targeted delivery (e.g., Lym-1 and SHALs bind specifically to HLA-DR10 on B-cell lymphoma cells, triggering immune destruction or facilitating targeted delivery of cytotoxic agents)
03
Biological functions
Immune response: presents exogenous peptide antigens to CD4+ T helper cells to trigger and modulate adaptive immunity
04
Disease associations
InfectionAutoimmunity (linked to susceptibility, e.g., lichen planus, rheumatoid arthritis)Cancer (notably ovarian cancer and squamous cell cervical cancer)
05
Safety considerations
Off-target immune activation (potential immunogenicity when targeting HLA-DR10 systemically)Polymorphism leading to variable expression and binding among individuals
06
Interacting drugs
Lym-1 (an antibody used in research and sometimes radioimmunotherapy against cells expressing HLA-DR10)
1 more in the full profile.
07
Biomarkers
HLA-DR10 expression is a biomarker for certain B-cell lymphomas (such as those derived from Raji cells), and may be used for diagnostic or prognostic purposes
Beyond the preview
Go deeper on Major histocompatibility complex, class II, DR beta 1 chain (HLA-DRB1*10:01) (HLA-DR10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Major histocompatibility complex, class II, DR beta 1 chain (HLA-DRB1*10:01) (HLA-DR10).